CONNECT WITH US
HealthTech

HealthTech

Digitally supported care model improves serum urate target attainment in gout

Medical Xpress logo

Published on

Add as a preferred source on Google
Digitally supported care model improves serum urate target attainment in gout

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

For patients with gout, a physician-supervised treat-to-target (T2T) care model improves serum urate (SUA) target attainment, according to a study published online Nov. 4 in Arthritis & Rheumatology.

Yining Gao, M.D., from the Tongji University School of Medicine in Shanghai, and colleagues conducted a 12-month, single-center, open-label superiority randomized controlled trial involving 280 men with gout. Participants were randomly assigned to an integrated physician-supervised T2T digitally supported care model (the "1CARE" platform combining automated behavioral reminders, tiered education, remote SUA monitoring and weekly physician review [App-Led Care]) or usual care (140 to each group).

The researchers found that at 12 months, 85.0% and 48.6% of participants in the App-Led Care group and the usual care group, respectively, achieved the primary therapeutic target of SUA <360 μmol/L (risk ratio, 1.75). In addition, significantly lower annualized gout flare frequency was seen in the App-Led Care group (0.02 versus 0.10 flares/year).

The App-Led Care group had favorable exploratory metabolic outcomes, with greater reductions in fasting plasma glucose, hemoglobin A1c, total cholesterol and low-density lipoprotein cholesterol, together with higher adherence to medication. The two groups had comparable adverse event rates.

"The integrated, physician-supervised, digitally supported '1CARE' care model demonstrated superiority over usual care in achieving serum urate targets and reducing gout flare frequency over 12 months, with exploratory evidence of favorable metabolic cobenefits," the authors write.

, Effects of a Smartphone‐Enabled, Physician‐Supervised Treat‐to‐Target Model for Gout Management: A 12‐Month Randomized Controlled Trial, Arthritis & Rheumatology (2026).


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.